title: Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients.
abstract: OBJECTIVE
  To determine renal function eligibility for cisplatin-based chemotherapy using our experience with radical cystectomy (RC) patients.
  
  
  METHODS
  Using the Mayo Clinic Cystectomy Registry, we identified 768 patients treated with RC without neoadjuvant chemotherapy for urothelial carcinoma from 1980-2005. Glomerular filtration rate (GFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and a value of ≥60 mL/min was considered eligible for cisplatin-based chemotherapy. Factors associated with change in GFR (from preoperative to 3-month postoperative) were assessed using linear regression.
  
  
  RESULTS
  The median age was 68 years, while the median GFR was 60 mL/min both preoperatively and 3 months after RC. Overall, 405 (53%) patients had a GFR of <60 mL/min before surgery and 387 (50%) had a GFR of <60 mL/min at 3 months after RC. Patients with hydronephrosis (209 patients) had significantly lower preoperative GFRs than with patients without hydronephrosis (median 52 vs 62 mL/min, respectively; P < 0.001). Among the 363 patients with a GFR of ≥60 mL/min before RC, 91 (25%) had a decline in renal function to a GFR of <60 mL/min at 3 months after RC. In multivariable analyses, older age (P < 0.001), higher preoperative GFR (P < 0.001) and continent urinary diversion (P = 0.011) were significantly associated with a negative change in GFR after RC.
  
  
  CONCLUSIONS
  Our results suggest that nearly half of patients undergoing RC are not eligible to receive perioperative cisplatin-based chemotherapy based on renal function status. About a quarter of patients eligible for cisplatin before surgery are no longer eligible after RC. Certain patient characteristics and surgical factors are more likely to experience a negative change in GFR after RC and should be counselled accordingly.
authors.affiliation: Department of Urology, Mayo Clinic and Mayo Medical School, Rochester, MN, USA.
authors.forename: R Houston
authors.initials: RH
authors.lastname: Thompson
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Boorjian
authors.forename: Simon P
authors.initials: SP
authors.lastname: Kim
authors.forename: John C
authors.initials: JC
authors.lastname: Cheville
authors.forename: Prabin
authors.initials: P
authors.lastname: Thapa
authors.forename: Robert
authors.initials: R
authors.lastname: Tarrel
authors.forename: Roxana
authors.initials: R
authors.lastname: Dronca
authors.forename: Brian
authors.initials: B
authors.lastname: Costello
authors.forename: Igor
authors.initials: I
authors.lastname: Frank
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use*; D015653:Cystectomy; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
keywords: cisplatin; cystectomy; glomerular filtration rate; urinary bladder neoplasms